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http://dx.doi.org/10protocol-based pulsed-dose-rate (PDR) interstitial
brachytherapy (iBT) in 385 patients with head and neck cancer who underwent PDR-iBT preferably
after minimal, nonmutilating surgery.
METHODS AND MATERIALS: From 1997 to 2009, a total of 385 patients received protocol-
based PDR-iBT for head and neck cancer. Brachytherapy was preceded by surgery in most of
our patients (326/385, 84.7%). Altogether, 246 of 385 patients (63.9%) received iBT alone and
135 of 385 patients (36.1%) in combination with external beam radiation therapy. The analysis
was done after a median followup of 63 months.
RESULTS: The 5-, 10-, and 15-year local relapse-free survival rates according to KaplaneMeier
test for all analyzed patients were 85.8%, 83.1%, and 80.2%, respectively. The 5-, 10-, and 15-year
overall survival and disease-free survival rates were 68.9%, 52.2%, and 44.1%, and 81.3%, 79.3%,
and 76.3%, respectively. For N0-/N1- vs. N2-patients, we observed significantly different 5-year
local recurrence-free survival rates with values of 92.3% and 73.7%, respectively ( p5 0.007).
No other patient or treatment-related parameters had a significant influence on treatment results.
Serious late side effects, such as soft tissue or bone necrosis, were observed in 39 of 385 patients
(10.2%) and 18 of 385 patients (4.9%), respectively.
CONCLUSIONS: The PDR-iBT with 0.4e0.7 Gy each hour, 24 h per day for patients with head
and neck cancer is a proven, effective, and safe treatment method with excellent long-term data.
 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.Keywords: Pulsed-dose-rate brachytherapy; Interstitial brachytherapy; Head and neckIntroduction
Interstitial brachytherapy (iBT) as a sole treatment or in
combination with external beam radiation therapy (EBRT)
is a valuable treatment modality in the treatment of both
primary and recurrent head and neck cancer. The results
of low-dose-rate (LDR) brachytherapy with 192Ir wires
using the rules of the Paris system were considered gold
standard in the therapy of preferably small head and neck
tumors up to the end of 20th century (1e14). Pulsed-
dose-rate (PDR) brachytherapy as a substitute for LDRil 2013; received in revised form 10 June 2013;
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.1016/j.brachy.2013.07.002brachytherapy is considered a useful option in the treatment
of head and neck tumors because it combines the biologic
advantages of LDR brachytherapy (15e18) with the tech-
nical advantages of the afterloading technique known from
high-dose-rate (HDR) brachytherapy.
This article presents a single-institution experience of
protocol-based PDR-iBT for 385 patients with special
emphasis on local control rate and late toxicity in patients
with squamous cell carcinoma of the oral cavity and of
the oropharynx who underwent PDR-iBT preferably after
minimal, nonmutilating surgery.Patients and methods
From October 1997 to December 2009, 385 patients
received protocol-based PDR-iBT for head and neck
cancer. Patient and tumor characteristics especially with re-
gard to tumor site and stage (Table 1) illustrate that most
patients had tumors of the oral cavity (72%). Mainly, thehed by Elsevier Inc. All rights reserved.
Table 1
Tumor characteristics
Characteristics Number of patients (N5 385), n (%)
Tumor site
Lip 14 (3.6)
Floor of mouth 118 (30.6)
Base of tongue 33 (8.6)
Mobile tongue 160 (41.6)
Soft palate 12 (3.1)
Tonsil 34 (8.8)
Buccal mucosa 11 (2.9)
Nasopharynx 2 (0.5)
Hard palate 1 (0.3)
Tumor stage
T1 172 (46.2)
T2 167 (44.9)
T3 17 (4.6)
T4 14 (3.8)
Tx 15 (4.0)
Nodal stage
N0 253 (65.7)
N1 56 (14.5)
N2 57 (14.8)
Nx 6 (1.6)
Histology
Squamous cell carcinoma 359 (96.5)
Adenoid cystic carcinoma 5 (1.3)
Others 8 (2.2)
Grading
G1 38 (10.2)
G2 221 (59.6)
G3 101 (27.2)
G4 2 (0.5)
Not classified 2 (0.5)
Not known 21 (5.4)
Lymphovascular invasion
Negative 197 (53.1)
Positive 87 (23.5)
Not known 101 (27.1)
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mous cell carcinomas with 91% being in Stage T1/T2.
In most of our patients (326/385, 84.7%), brachytherapy
was preceded by surgery. The surgical procedures for all
these patients included tumor resection with neck dissec-
tion. The time interval between surgery and radiation
therapy was 63 days (median). The indication for postoper-
ative brachytherapy predominantly was positive or close
resection margins (#2 mm), or in the case of clear resec-
tion margins if there were risk factors such as a depth of
tumor invasion of more than 5 mm, lymphovascular inva-
sion, or histopathologic grading of 3 or 4. Clear resection
margins had been achieved in 300 of 326 (92%) patients.
The median value for depth of tumor invasion was
7.0 mm. A total of 139 of 385 patients (37.4%) with large
tumors or positive lymph nodes were treated in addition
with EBRT with a median dose of 55 Gy. The median for
the time interval between EBRT and brachytherapy was 9
days. All patients were treated with PDR-iBT with 192Ir.
All implants were done under general anesthesia using
plastic tubes and respecting the rules of InternationalCommission on Radiation Units and Measurements 58
(19) as described by us in detail earlier (20, 21). A dose
per pulse (dp) with a median value of 0.55 Gy (range,
0.4e0.7 Gy) was used, delivered for 24 h per day with
a time interval of 1 h between pulses. The median volume
of the 85% isodose (reference isodose) was 23.4 cm3. The
median values for the dose homogeneity index and the dose
nonuniformity ratio were 0.76 and 0.27, respectively. For
113 of the 385 (29%) patients treated since 2007, a delinea-
tion of the clinical target volume (CTV) and the organs at
risk using CT-based treatment planning has also been per-
formed. The CTV encompassed the macroscopic tumor/
tumor bed (gross tumor volume) and a 5e10-mm safety
margin in all directions respective of natural, anatomic
borders such as bone, the lingual edge, and the skin. In
postoperative cases, the tumor bed contour (gross tumor
volume) included all clinically visible and palpable surgical
scars. For CT-based planning, the dose distribution was
normalized on reference points in the central plane accord-
ing to International Commission on Radiation Units and
Measurements 58. Thereafter, a geometric optimization
was done to achieve the best possible dose homogeneity.
In a last step, the dwell times were adjusted manually or
using graphical optimization aiming to achieve a satisfac-
tory coverage of the CTV. Here also, the coverage index
V100 (median, 93.3%) and D90 (median, 103.8%) were
documented.
A total of 246 of the 385 patients (63.9%) received iBT
procedures alone using a median total dose of 57 Gy. In
combination with EBRT, PDR-iBT was performed with
a median total dose of 24 Gy. The median time interval
between external irradiation and brachytherapy was 9 days.
The EBRTwas performed up to a median reference dose of
55 Gy.
Patients with T4 tumors or positive lymph nodes with
extracapsular tumor extension (47/385, 12.6%) additionally
received simultaneous chemotherapy in the first and fifth
weeks of EBRT using Cis-/Carboplatin and 5-fluorouracil.
The statistical analysis was performed with the SPSS
18.0 software (IBM Corp., New York). The actuarial curves
were calculated according to the KaplaneMeier method
(22). The comparisons were made using the log-rank test
or Cox regression analysis or the KruskaleWallis test as
appropriate. All patients were followed closely to analyze
local control, survival, as well as acute and late toxicity.
The analysis was performed after a median followup of
63 months. The followup was calculated from the first
day of radiation therapy to the date of last followup.Results
The 5-, 10-, and 15-year local relapse-free survival rates
according to KaplaneMeier test for all analyzed patients
were 85.8%, 83.1%, and 80.2%, respectively (Fig. 1). The
5-, 10-, and 15-year overall survival and disease-free
Fig. 1. Local control rate according to KaplaneMeier analysis for all
patients.
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79.3%, and 76.3%, respectively. There were a total of 48
local recurrences (LRs) among the 385 patients: 16 LR
for the 172 T1 patients, 25 LR for the 167 T2 patients, 5
LR for the 17 T3 patients, and 2 LR for the 14 T4 patients.
Nearly, all LRs (40/48) developed in the first 3 years after
therapy, the mean time to LR was 20 26 months (Fig. 2).Fig. 2. Cumulative incidence of the risk of local recurrence for all
patients.The 5-and 10-year LR-free survival rates of the entire
group according to tumor size and nodal status were
91.3% and 90.5 for stage T1/2 N0/1 and 80% for stage
T1/2 N2, respectively (Fig. 3). For the small number of
patients with large tumors such as T3/4 N0/1 or T3/4N2
(31/385), the 5-year LR-free and overall survival rates were
88.9% and 51.1%, respectively.
In the detailed analysis of all patients, we did not iden-
tify any statistically significant differences with respect to
anatomic site or tumor size. We found a significant influ-
ence of the extent of lymph node involvement on treatment
results. In N0-/N1- vs. N2-patients, we observed signifi-
cantly different 5-year LR-free survival rates with values
of 92.3% and 73.7%, respectively ( p5 0.007, Fig. 4). No
other tumor- or patient-related factor showed a significant
correlation with treatment results either in univariate or
multivariate analysis. Regarding treatment factors, we only
identified surgery to have a significant influence on treat-
ment results. The 5-year LR-free survival was 93.4% with
surgery and 72% without surgery ( p5 0.002). In this
context, it is important to note that there was a considerable
negative selection bias affecting prognosis in patients
without surgerydfor patients with or without surgery, large
tumors (T3/T4) were recorded in 6.5% and 25%, respec-
tively and N2 status in 12.1% and 37.5%, respectively.
During followup, we observed metastases in 41 of 385
patients (10.6%). Only 13 of 385 (3.4%) patients developed
regional lymph node metastases, the other 28 of 385 (6.2%)
patients developed distant metastases. The median time to
appearance of metastases was 12 months.
Serious late side effects, such as soft tissue or bone
necrosis, were observed in 39 of 385 patients (10.2%)
and 18 of 385 patients (4.9%), respectively. In patients withFig. 3. Local control rate according to KaplaneMeier analysis for
patients with small tumors (T1/T2) according to lymph node status.
Fig. 4. Local control rate according to KaplaneMeier analysis for all
patients according to lymph node status.
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sary in 13 of 39 (13/385, 3.4%) patients; in patients with
bone necrosis, surgical treatment was necessary in 13 of
18 (13/385, 3.4%) patients.Discussion
For tumors of the oral tongue treated with primary LDR
brachytherapy, we know from large retrospective series that
the local control rate strongly depends on tumor size and
varies between 62e69% for T3 tumors and 88e93% for
T1 tumors (2e8, 10, 21, 23e27). Treatment success is
strongly related to the total dose and the dose rate as shown
in the results presented by Mazeron et al. (2, 26) and Simon
et al. (9)dthese should be higher than 62.5 Gy and higher
than 0.5 Gy/h, respectively. The published local control
rates for oral cavity cancer vary between 75% and 90%
and are strongly related to tumor size, total dose, and dose
rate. For oropharyngeal carcinomas without surgery treated
with LDR brachytherapy combined with EBRT, the largest
series were reported by Senan and Levendag (28). The 5-
year local control rates in 243 patients were between 67%
(T3 tumors) and 87% (T1/T2 tumors). Similar results were
reported from other centers (14, 29e31). Some of the best
results for brachytherapy as boost for early oropharyngeal
cancer without surgery has been reported recently by Al-
Mamgani et al. (32)dfor 167 patients, a 5-year local
control rate of 94% was achieved. In the postoperative
setting, brachytherapy as boost (pT1/T2 pNþ patients)
and in particular postoperative brachytherapy alone (pT1/
T2 pN0 patients) offers the patients the same 5-year local
control rates as EBRTdabout 90% (4, 11, 21, 26,
33e36)dwith much lower side effects. Brachytherapyavoids xerostomia, extensive mucositis affecting the whole
oral cavity, trismus, and also permits future radiation
therapy of possible secondary tumors in the head and neck
area owing to the excellent protection of surrounding
healthy tissues.
Radiobiologic studies have shown that PDR brachyther-
apy is probably equivalent to LDR brachytherapy models
(15e18, 37e44). Clinical data derived from different clin-
ical situations has provided some evidence to support this
hypothesis (20, 21, 45e55). Unfortunately up to now, for
head and neck cancer treated with PDR brachytherapy, only
a limited amount of experience has been presented in the
literaturedmostly in the form of feasibility studies with
limited patient numbers (26, 47e49, 51, 56, 57). The
French experiences with PDR brachytherapy for 30 head
and neck cancer patients (51) have only been able to show
that PDR brachytherapy is feasible and that 14 of 28
patients had short or definitive breakdown of therapy owing
to different problems. Similarly, de Pree et al. (49) have
shown in 17 patients that PDR brachytherapy is feasible.
Levendag et al. (56) have treated 38 patients with head
and neck cancer with PDR brachytherapy (dp5 2 Gy,
4e8 times/d) alone or in combination with EBRT. The
patients showed better local control as compared with
a historical control group (87% vs. 61%).
Some centers have also introduced daytime PDR sched-
ules to avoid hospitalization and to reduce overall treatment
costs. Whether it is possible to restrict PDR irradiation only
to office hours without compromising therapy efficacy (53,
58) remains controversial. Until now, no long-term results
of any study support this suggestion. We believe that only
the complete 24-h treatment schedule guarantees that
PDR brachytherapy will preserve all the radiobiologic
advantages of LDR brachytherapy. In our experience, there
exist no logistical or practical problems with the 24-h treat-
ment schedule of PDR brachytherapy administered for 3e6
days.
If we compare our results from PDR-iBT in head and
neck cancer, mostly administered as postoperative brachy-
therapy, with the results from LDR brachytherapy (14,
33e35, 59, 60), we see prevailing similarities in the results.
The reported local control rates depend on the tumor size
have values between 78% and 93% for T1/T2 tumors and
57% for T3/T4 tumors (3, 6, 14, 21, 27, 33, 34, 59, 60).
Local control rates in our study also correlate with tumor
size and reach 86% after 5 years and 83% after 10 years
for all patients. In this context, it is necessary to mention
the limitations of the KaplaneMeier method for local
control estimates because competing events such as deaths
from other causes can modify the results. Nonetheless, it is
obvious that such excellent local control rates have been
achievable only in the era of modern image-guided brachy-
therapy, with optimal interleaving of brachytherapy and
nonmutilating surgery. In this context, our results are also
congruent with excellent results of Al-Mamgani et al.
(32). Recently, there has also been a sharp increase in the
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neck tumors. Data relating to HDR brachytherapy in the
treatment of head and neck cancer have been largely retro-
spective (21, 56, 61e70), but there exists one randomized
study (65) with a relatively small number of patients.
Unfortunately, in the randomized study, only 59 patients
were analyzed and therefore no valid conclusions can be
drawn. The retrospective results seem to indicate that the
results of HDR brachytherapy may be similar to the results
of LDR and PDR brachytherapy.
The most feared serious side effects are soft tissue and
bone necrosis. The probability for this complication depends
in particular on the total dose, dose rate, intersource spacing,
implant volume, quality index, and volume gradient ratio
(9, 27, 71e73). Osteoradionecrosis also correlate with the
distance between the sources and the bone. The risk of soft
tissue necrosis in LDR brachytherapy varies between 20%
and 30%dmost of these lesions heal spontaneously and
necrosis of bone may occur in about 10e20% of the patients.
For example, Lapeyre et al. (35) reported late complications
in 34 of 82 patients (43%), 8 of them (9.8%) were in Grade 3.
Beitler et al. (33) reported a high rate of late side
effectsdwith severe or moderate late sequelae being seen
in 12 of 23 patients (52.2%). Similarly, in a series reported
by Mendenhall et al. (36), 7 of 15 patients (46.7%) devel-
oped serious late complication. In our study, we registered
serious late side effects in 5e10% of the patients with only
3.4% suffering from soft tissue or bone necrosis requiring
surgery. We suggest that these low complication rates are
first owing to the exclusive use of PDR brachytherapy in
all patients, a therapy method, which unites the biologic
advantages of LDR brachytherapy with the technical
advantagesdthe stepping source technologydof the
HDR-afterloading method and second owing to consequent
consideration of quality assurance (72).
The results of our protocol-based study in 385 patientsd
up to date the largest series worldwideddemonstrate that
PDR brachytherapy is really biologically equivalent to
LDR brachytherapy. The presented results confirm the
radiobiologic hypothesis that PDR brachytherapy is indis-
tinguishable from continuous LDR brachytherapy, if the
pulses are given for more than 3e7 days once per hour,
24 h per day with dps of between 0.4 and 0.7 Gy.
Moreover, it seems that owing to the possibility of opti-
mization of the source times, the results of PDR brachyther-
apy may be superior to the results of LDR brachytherapy in
terms of its potential for individualization and the possi-
bility of a better treatment scheduledin particular
regarding late side effects.Conclusions
The PDR-iBT with dps of 0.4e0.7 Gy each hour, 24 h
per day for the treatment of head and neck cancer inselected patients is a proven, effective, and safe treatment
method with excellent long-term data.References
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